**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Sabrina Rebello, Amyloidosis Research Consortium, Newton, MA

**Main Body of the Abstract**
Introduction Transthyretin amyloidosis (ATTR) is a fatal disease caused by the misfolding of the protein, transthyretin (TTR). ATTR amyloidosis can be caused by genetic mutations (ATTRv) or age-related (ATTRwt). This study examined ATTR-related quality of life (QOL) among patients with ATTRv and ATTRwt.
Methods The Amyloidosis Research Consortium (ARC) conducted a multi-country online survey of patients with ATTR amyloidosis in 2023. Survey measures included demographics, disease characteristics, and the Transthyretin Amyloidosis Quality of Life (ATTR-QOL). The ATTR-QOL measures the impact of ATTR on daily activities, social/role functioning, emotional wellbeing, and physical functioning, with higher scores indicating greater impact. Differences by genotype were evaluated with t-tests.
Results Of the 309 ATTR respondents included in this analysis, the majority (n=220 [71%]) had ATTRwt with 89 ATTRv patients, 37 of whom had Thr60Ala (T60A) TTR mutation, 34 had Val30Met (V30M) TTR mutation, and 18 had Val122Ile (V122I) TTR mutation. Mean (standard deviation [SD]) years since diagnosis were 4 (4) for ATTRwt, T60A ATTRv, and V122I ATTRv patients and 7 (6) for V30M ATTRv patients. V122I ATTRv patients had the highest mean ATTR-QOL impact score (44.7[24.7]); ATTRwt patients had the lowest (24.4 [20.1]) (Figure). Mean Daily Activities and Social/Role Functioning scores were higher among V1221 ATTRv patients (p<0.05). While not statistically significant, Emotional Wellbeing and Physical Functioning scores were also highest among V122I ATTRv patients.
Conclusions ATTR amyloidosis has an impact on patients’ QOL. The results of this study suggest that disease burden differs across genotype, with the greatest impact among V122I ATTRv patients.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Sabrina Rebello, Amyloidosis Research Consortium, Newton, MA

**Main Body of the Abstract**
**Introduction** Transthyretin amyloidosis (ATTR) is a fatal disease caused by the misfolding of the protein, transthyretin (TTR). ATTR amyloidosis can be caused by genetic mutations (ATTRv) or age-related (ATTRwt). This study examined ATTR-related quality of life (QOL) among patients with ATTRv and ATTRwt.
**Methods** The Amyloidosis Research Consortium (ARC) conducted a multi-country online survey of patients with ATTR amyloidosis in 2023. Survey measures included demographics, disease characteristics, and the Transthyretin Amyloidosis Quality of Life (ATTR-QOL). The ATTR-QOL measures the impact of ATTR on daily activities, social/role functioning, emotional wellbeing, and physical functioning, with higher scores indicating greater impact. Differences by genotype were evaluated with t-tests.
**Results** Of the 309 ATTR respondents included in this analysis, the majority (n=220 [71%]) had ATTRwt with 89 ATTRv patients, 37 of whom had Thr60Ala (T60A) TTR mutation, 34 had Val30Met (V30M) TTR mutation, and 18 had Val122Ile (V122I) TTR mutation. Mean (standard deviation [SD]) years since diagnosis were 4 (4) for ATTRwt, T60A ATTRv, and V122I ATTRv patients and 7 (6) for V30M ATTRv patients. V122I ATTRv patients had the highest mean ATTR-QOL impact score (44.7[24.7]); ATTRwt patients had the lowest (24.4 [20.1]) (Figure). Mean Daily Activities and Social/Role Functioning scores were higher among V1221 ATTRv patients (p<0.05). While not statistically significant, Emotional Wellbeing and Physical Functioning scores were also highest among V122I ATTRv patients.
**Conclusions** ATTR amyloidosis has an impact on patients’ QOL. The results of this study suggest that disease burden differs across genotype, with the greatest impact among V122I ATTRv patients.



Quality of Life of Patients with Variant and Wild-Type Transthyretin Amyloidosis PC42 (#316)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.